ライフサイエンスコーパス: 18F-fluorodeoxyglucose

1 rcinoma were correctly detected by PET using 18F-fluorodeoxyglucose.

2 opsychological testing, and PET imaging with 18F-fluorodeoxyglucose.

3 cerebral glucose metabolism determined with 18F-fluorodeoxyglucose.

4 ain were reported previously using PET with [18F]fluorodeoxyglucose.

5 ers with positron emission tomography using [18F]fluorodeoxyglucose.

6 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel bio

7 uptake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active pl

8 ssessed by 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of

9 Metabolic imaging with 18F-fluorodeoxyglucose ([18F]FDG) occurred 28 and 58 day

10 Whole-body 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomo

11 We performed dynamic [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomo

12 s examined by magnetic resonance (MR) or by [18F]fluorodeoxyglucose ([18F]FDG) uptake by positron emi

13 C]MeNTI and [11C]carfentanil ([11C]CFN) and [18F]fluorodeoxyglucose ([18F]FDG), respectively.

14 Recent studies using PET with 18F-fluorodeoxyglucose (18FDG) have shown the presence o

15 re myocardial blood flow in combination with 18F-fluorodeoxyglucose (18FDG) to assess myocardial viab

16 w prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomogra

17 The glucose analogue [18F]-fluorodeoxyglucose (18FDG) can be used to image inf

18 aging of positron-emitting tracers, such as [18F]fluorodeoxyglucose (18FDG), possible.

19 educed glucose metabolism, identified using [18F]fluorodeoxyglucose (18FDG), that is commonly more ex

20 used leukocyte uptake of the glucose analog [18F]fluorodeoxyglucose (18FDG), which indicates postmigr

21 Positron emission tomographic imaging with [18F]fluorodeoxyglucose ([18FDG]) could be used as a noni

22 y tracer used for assessment of viability is 18F-fluorodeoxyglucose, a glucose analogue that exhibits

23 sitron emission tomography imaging utilizing 18F-fluorodeoxyglucose and perfusion tracers provides va

24 raphy (PET) to measure CBF (N = 19) or with [18F] fluorodeoxyglucose and PET to measure cerebral gluc

25 Positron emission tomography with [18F]fluorodeoxyglucose and matching MRI scans were obtai

26 We have used [18F]fluorodeoxyglucose and PET to identify specific meta

27 Imaging with [18F]fluorodeoxyglucose and positron emission tomography

28 DYT1 carriers and 14 normal volunteers with [18F]fluorodeoxyglucose and positron emission tomography.

29 erformed positron emission tomography using [18F]fluorodeoxyglucose and structural magnetic resonance

30 ex (measuring brain glucose metabolism with [18F]fluorodeoxyglucose) and dopamine increases (measured

31 -CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practi

32 d flow (with [15O]H2O) and metabolism (with [18F]fluorodeoxyglucose) before the start of therapy and

33 ed agents: metabolism can be identified with 18F fluorodeoxyglucose (FDG), receptor expression with 9

34 effect of insulin on myocardial kinetics of 18F-fluorodeoxyglucose (FDG) and glucose in patients wit

35 nd Yahr stage 3.8 +/- 1.0) with quantitative 18F-fluorodeoxyglucose (FDG) and positron emission tomog

36 body PET on a patient and lesion basis using 18F-fluorodeoxyglucose (FDG) for the detection of tumor

37 Whole-body PET imaging with 18F-fluorodeoxyglucose (FDG) has been shown to be effect

38 a case of Castleman's disease demonstrating 18F-fluorodeoxyglucose (FDG) localization by whole-body

39 stained a mild traumatic brain injury had an 18F-fluorodeoxyglucose (FDG) PET brain study using coinc

40 imize the semiquantitative interpretation of 18F-fluorodeoxyglucose (FDG) PET scans in the diagnosis

41 e knottin peptide are compared with standard 18F-fluorodeoxyglucose (FDG) PET small animal imaging.

42 metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomograph

43 rience with coincidence detection imaging of 18F-fluorodeoxyglucose (FDG) using a dual-head gamma cam

44 PET, using the radiotracer 18F-fluorodeoxyglucose (FDG), permits the measurement of

45 fine the total body distribution kinetics of 18F-fluorodeoxyglucose (FDG), to contribute to its radia

46 by positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG).

47 mb perfusion and underwent PET scanning with 18F-fluorodeoxyglucose (FDG).

48 f tumor energetics, obtained by imaging with 18F-fluorodeoxyglucose (FDG).

49 reperfusion with PET and the glucose analog 18F-fluorodeoxyglucose (FDG).

50 sion tomography with metabolic tracers like [18F]-fluorodeoxyglucose (FDG) also appears to offer new

51 orcine myocardial stunning on the uptake of [18F]-fluorodeoxyglucose (FDG) at 24 hr and 7 days after

52 At each timepoint they were scanned with [18F]-fluorodeoxyglucose (FDG) to assess longitudinal cha

53 Using dynamic [18F]fluorodeoxyglucose (FDG) and PET, kinetic rate const

54 regions of the conscious rodent brain using [18F]fluorodeoxyglucose (FDG) as the tracer, and to monit

55 Quantitative [18F]fluorodeoxyglucose (FDG) PET has considerable potent

56 The reliability of serial [18F]fluorodeoxyglucose (FDG) PET scans for psychopharmac

57 In a previous [18F]fluorodeoxyglucose (FDG) PET study we analyzed regio

58 Dynamic [18F]fluorodeoxyglucose (FDG) PET was used in Parkinson's

59 treatment correlate with tumor responses by [18F]fluorodeoxyglucose (FDG) positron emission tomograph

60 [18F]fluorodeoxyglucose (FDG) positron emission tomograph

61 Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomograph

62 ology and behavioral imaging with muPET and [18F]fluorodeoxyglucose (FDG) to generate whole-brain met

63 -handed men underwent scanning with PET and [18F]fluorodeoxyglucose (FDG) twice: before placebo and b

64 ested with positron emission tomography and [18F]fluorodeoxyglucose (FDG) under resting conditions; e

65 Positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) were used to measure region

66 We have used [18F]fluorodeoxyglucose (FDG) with PET to identify region

67 nstance, the radiolabeled glucose analogue, [18F]fluorodeoxyglucose (FDG), is routinely used in posit

68 -handed men were scanned twice with PET and [18F]fluorodeoxyglucose (FDG): before placebo and before

69 However, a whole-body PET scan with [18F]fluorodeoxyglucose (FDG-PET) was negative in these r

70 egistered positron emission tomography with [18F]fluorodeoxyglucose for metabolic assessment and core

71 rogen-13 ammonia imaging, and metabolism by [18F]-fluorodeoxyglucose imaging.

72 of positron emission tomography (PET) with [18F]fluorodeoxyglucose in eight younger (mean age = 35 y

73 sured with positron emission tomography and [18F]fluorodeoxyglucose in five methamphetamine abusers w

74 ositron emission tomographic measurement of [18F]fluorodeoxyglucose myocardial distribution also was

75 eshold for defining brain boundaries in both 18F-fluorodeoxyglucose (n = 8) and 15O-water (n = 12) PE

76 r the study because of the prominent role of 18F-fluorodeoxyglucose PET in the staging of lung cancer

77 ed longitudinally with [11C]-raclopride and [18F]-fluorodeoxyglucose PET imaging, with scans at basel

78 fest HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metaboli

79 n, [18F]FLT-PET was found to be superior to [18F]fluorodeoxyglucose-PET (NUV60 versus LIPCNA: r = 0.8

80 ting cerebral metabolism was measured using [18F]fluorodeoxyglucose-PET and analysed with the techniq

81 Each subject underwent [18F]fluorodeoxyglucose-PET and neuropsychological testin

82 18F-fluorodeoxyglucose positron emission tomography (18F

83 The introduction of 18F-fluorodeoxyglucose positron emission tomography (18F

84 variables, atrophy on MRI, hypometabolism on 18F-fluorodeoxyglucose positron emission tomography (FDG

85 uantification software application to hybrid 18F-fluorodeoxyglucose positron emission tomography (PET

86 Cerebral 18F-fluorodeoxyglucose positron emission tomography in 1

87 18F-fluorodeoxyglucose positron emission tomography was

88 ential benefit of prompt diagnosis, aided by 18F-fluorodeoxyglucose positron emission tomography, and

89 independent predictor of thyroid malignancy; 18F-fluorodeoxyglucose positron emission tomography, whi

90 rial and LN inflammation were measured using 18F-fluorodeoxyglucose positron emission tomography.

91 We report two cases of SOS investigated by 18F-fluorodeoxyglucose positron emission tomography/comp

92 ethylation status, and metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

93 Response to treatment was evaluated using [18F] fluorodeoxyglucose positron emission tomography (PE

94 gnal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PE

95 Magnetic resonance and [18F]-fluorodeoxyglucose positron emission tomography bra

96 tients were scanned with both [15O]-H2O and [18F]-fluorodeoxyglucose positron emission tomography in

97 and Alzheimer's disease (AD) patients with [18F]-fluorodeoxyglucose positron emission tomography usi

98 To study whether changes of [18F]fluorodeoxyglucose positron emission tomography (FDG

99 The subjects underwent two [18F]fluorodeoxyglucose positron emission tomography scan

100 es of mood and cerebral glucose metabolism ([18F]fluorodeoxyglucose positron emission tomography) dur

101 able Alzheimer's disease is possible, using [18F]fluorodeoxyglucose positron emission tomography.

102 ast spin echo images of the temporal lobes; [18F]fluorodeoxyglucose-positron emission tomographic sca

103 tified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET

104 kin lesions confirmed the same disease, and [18F]fluorodeoxyglucose-positron emission tomography demo

105 In recent years metabolic imaging with [18F]fluorodeoxyglucose-positron emission tomography has

106 ver ultrasounds, computed tomography scans, [18F]fluorodeoxyglucose-positron emission tomography scan

107 ssion tomography techniques: [15O]water and [18F]fluorodeoxyglucose, respectively.

108 Positron emission tomography with [18F]fluorodeoxyglucose revealed widespread hypometabolis

109 n (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeoxyglucose scanning.

110 omography with sestamibi or tetrofosmin, and 18F-fluorodeoxyglucose single-photon emission computed t

111 twice with positron emission tomography and [18F]fluorodeoxyglucose; the first scan was obtained afte

112 ilability of dopamine D2 receptors and with [18F]fluorodeoxyglucose to assess regional brain glucose

113 phy was used with [11C]flumazenil (FMZ) and [18F]fluorodeoxyglucose to study GABA type A/benzodiazepi

114 Positron emission tomography with an [18F]fluorodeoxyglucose tracer was used in a within-subje

115 The finding of enhanced 18F-fluorodeoxyglucose uptake and a relative reduction i

116 , we found that the changes in [18F]FLT and [18F]fluorodeoxyglucose uptake were due to changes in lev

117 Positron emission tomography (PET) with [18F]fluorodeoxyglucose was used to determine cerebral me

118 Positron emission tomography with [18F]fluorodeoxyglucose was used to determine cerebral me